Multi-Ingredient Supplementation in Professional Football Players
NCT07604519, Not applicable, Completed, Vizja University in Warsaw
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Multi-Ingredient Supplementation in Professional Football Players | ClinicalTrials.gov |
| NCT number | NCT07604519 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 97 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Vizja University in Warsaw | ClinicalTrials.gov |
| Conditions | Sports Performance, Cognitive Performance During Physical Activity, Fatigue, Recovery, Football Players | ClinicalTrials.gov |
| Interventions | Placebo, taurine, Caffeine, Phosphatidylserine | ClinicalTrials.gov |
| First posted | 2026-05-22 | ClinicalTrials.gov |
| Last updated | 2026-07-02 | ClinicalTrials.gov |
Registered outcomes 18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | 30 m sprint time | Baseline and after 14 days of supplementation | Time required to complete a 30 m sprint, measured using electronic timing gates. The best result from three maximal sprint trials will be used for analysis. Unit of Measure: seconds | ClinicalTrials.gov |
| Secondary | Change in sprint count between first and second half | After 14 days of supplementation, during the standardized football-specific training session | Percentage decline in the number of sprints between the first and second half of the standardized football-specific training session. Sprint change will be calculated as: \[(second half value - first half value) / first half value\] × 100. Unit of Measure: percent | ClinicalTrials.gov |
| Secondary | Visual reaction time | Baseline and after 14 days of supplementation | Mean response time to a visual stimulus, measured using a validated visual reaction time test. | ClinicalTrials.gov |
| Secondary | Auditory reaction time | Baseline and after 14 days of supplementation | Mean response time to an auditory stimulus, measured using a computerized auditory reaction time test. | ClinicalTrials.gov |
| Secondary | Total distance covered | After 14 days of supplementation, during the standardized football-specific training session | Total distance covered during the standardized football-specific training session, measured using a 10-Hz GPS tracking system. Unit of Measure: meters | ClinicalTrials.gov |
| Secondary | Relative distance | After 14 days of supplementation, during the standardized football-specific training session | Distance covered per minute during the standardized football-specific training session, measured using a 10-Hz GPS tracking system. Unit of Measure: meters per minute | ClinicalTrials.gov |
| Secondary | High-speed running distance | After 14 days of supplementation, during the standardized football-specific training session | Description: Distance covered at running speeds above 19.8 km/h during the standardized football-specific training session, measured using a 10-Hz GPS tracking system. Unit of Measure: meters | ClinicalTrials.gov |
| Secondary | Number of sprints | After 14 days of supplementation, during the standardized football-specific training session | Total number of sprint efforts performed during the standardized football-specific training session. Sprinting will be defined as running speed above 25.0 km/h and measured using a 10-Hz GPS tracking system. Unit of Measure: number of sprints | ClinicalTrials.gov |
| Secondary | Player Load | After 14 days of supplementation, during the standardized football-specific training session | External training load during the standardized football-specific training session, measured using triaxial accelerometry integrated with the GPS tracking system. Unit of Measure: arbitrary units | ClinicalTrials.gov |
| Secondary | Heart rate variability RMSSD | Daily during the 14-day supplementation period | Resting heart rate variability assessed in the morning using the root mean square of successive differences between normal heartbeats. HRV will be measured using a heart rate sensor or wearable device under standardized resting conditions. Unit of Measure: milliseconds | ClinicalTrials.gov |
| Secondary | Sleep duration | Daily during the 14-day supplementation period | Total sleep duration assessed using wearable sleep monitoring. Unit of Measure: hours | ClinicalTrials.gov |
| Secondary | Sleep efficiency | Daily during the 14-day supplementation period | Percentage of time in bed spent asleep, assessed using wearable sleep monitoring. Unit of Measure: percent | ClinicalTrials.gov |
| Secondary | Subjective fatigue | Daily during the 14-day supplementation period | Subjective fatigue assessed using the fatigue item of the Hooper Index questionnaire on a 1-7 scale, where higher values indicate greater fatigue. Unit of Measure: score on a scale | ClinicalTrials.gov |
| Secondary | Muscle soreness | Daily during the 14-day supplementation period | Perceived lower-limb muscle soreness assessed using a 0-10 delayed onset muscle soreness scale, where higher values indicate greater soreness. Unit of Measure: score on a scale | ClinicalTrials.gov |
| Secondary | Stroop task reaction time | Baseline and after 14 days of supplementation | Mean response time during a modified computerized Stroop task assessing cognitive fatigue, inhibitory control, sustained attention, and information processing speed. Unit of Measure: seconds | ClinicalTrials.gov |
| Secondary | Stroop task accuracy | Baseline and after 14 days of supplementation | Percentage of correct responses during a modified computerized Stroop task. Unit of Measure: percent | ClinicalTrials.gov |
| Secondary | Stroop task error rate | Baseline and after 14 days of supplementation | Number of incorrect responses during a modified computerized Stroop task. Unit of Measure: number of errors | ClinicalTrials.gov |
| Secondary | Perceived mental fatigue | Baseline and after 14 days of supplementation | Subjective perceived mental fatigue assessed using a 0-10 visual analogue scale, where higher values indicate greater perceived mental fatigue. Unit of Measure: score on a 0-10 scale | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)